3-氯-4-氟苯胺亚甲基丙二酸二乙酯在惰性高沸点溶剂中的环化反应

用 ~1HNMR 方法测定了3-氯-4-氟苯胺亚甲基丙二酸二乙酯在二苯醚或石蜡油中加热环化所得产物中2与3的比例,结果表明此比例随着溶剂的不同而稍有变化,并且副产物3的组份随着溶剂用量增大而减少。     

Guanidinium-carboxylate interactions

The crystal structures of the 1:1 complexes methylguanidinium benzylhydrogenmalonate, (C₂N₃H₈)⁺(C₁₀H₉O₄)^?, MGD.BMAL, and methylguanidinium ethylhydrogenmalonate, (C₂N₃H₈)⁺(C₅H₇O₄)^?, MGD.EMAL, and of the 2:1 complex methylguanidinium sulfate, (C₂N₃H₈)₂SO₄, have been determined from three-dimensional X-ray data. For MGD.BMAL, the complex crystallizes in the triclinic space group P with two formula units in a cell of dimensions a = 6.277(5), b = 8.470(3), c = 13.191(6)Å, α= 91.01(1), β= 99.64(9), γ= 90.83(5)°. The structure has been refined to a final value of R = 0.061 based on 1511 intensities. The MGD.EMAL complex is also triclinic, space group P with two molecules in a cell of dimensions a = 9.254(7), b = 9.625(6), c = 6.778(2) Å, α= 109.6(1), β= 100.8(1), γ= 62.7(1)Å. The crystals of this compound are of low quality, and the final value is R = 0.109 based on 706 intensities. (MGD)₂SO₄ is orthorhombic, space group P2₁2₁2₁, with four molecules in a cell of dimensions a = 7.100(4), b = 12.151(3), c = 13.108(2) Å. Refinement has converged to R = 0.054 based on 907 data. All three crystals exhibit extensive interionic hydrogen bonding. The hydrogen bonding in MGD.BMAL includes a Type B interaction and a Type 1 interaction, the latter being a pairwise interaction from both amino nitrogen atoms on the cation to two carboxylate oxygen atoms from the two different carboxylate groups in an anion. In MGD.EMAL, the anion participates in both a Type A and a Type B pairwise interaction with two neighboring cations. The possible implications of the hydrogen bonding patterns in these two compounds for the role of arginyl side chains in protection of γ-carboxyglutamate residues from decarboxylation are discussed.     

Analytical Chiral Separation of the Stereoisomers of a Novel Carbonic Anhydrase Inhibitor and Its Deethylated Metabolite,and the Assignment of Absolute Configuration of the Human Metabolite and Chiral Degradation Products

Several approaches to the separation of four stereoisomers, 1–4, of a novel, topically active, carbonic anhydrase inhibitor, 1, with two chiral centers in the molecule and four isomers, 5–8, of its chiral metabolite, 5, were evaluated. These methods include nonchiral derivatization followed by separation on chiral stationary phases (CSPs) and chiral derivatization and separation on nonchiral columns and on CSPs. Baseline separation of stereoisomers 1–4 was achieved in less than 15 min after chiral derivatization with (S)-(+)-l-(l-naphthyl)ethyl isocyanate (NEIC) and chiral chromatography on a (R)-N-(3,5-dinitrobenzoyl)phenyl glycine (DNBPG) column under normal phase (NP) conditions. Similarly, isomers 5-8 were baseline separated in less than 20 min after derivatization with NEIC and chromatography on nonchiral (nitrophenyl) and chiral [(S)-(3,5-dinitrobenzoyl)leucine; DNBL] columns in series under the same NP chromatographic conditions. Only partial separation of the diastereomeric derivatives was observed on a variety of nonchiral columns. In addition, all other direct and indirect chiral separation approaches gave only partial separation of at least two stereoisomers within the group of 1–4 or 5–8. The details of chiral separations using various methods and separation () and capacity factors (k) of the derivatized isomers 1–8 on a series of chiral and nonchiral columns are presented. Using these methods, the absolute configuration of the human metabolite of 1 was established as S ₁ S ₂ (5), and the heat (HD) and light (LD) degradation products of 1 as R ₁ S ₂ (3) and S₁ S ₂ (5), respectively.     

Nuclear TAR DNA-binding protein 43 A new target for amyotrophic lateral sclerosis treatment

Abnormal TAR DNA-binding protein 43 （TDP-43） inclusion bodies can be detected in the degen- erative neurons of amyotrophic lateral sclerosis. In this study, we induced chronic oxidative stress injury by applying malonate to cultured mouse cortical motor neurons. In the later stages of the malonate insult, TDP-43 expression reduced in the nuclei and transferred to the cytoplasm. This was accompanied by neuronal death, mimicking the pathological changes in TDP-43 that are seen in patients with amyotrophic lateral sclerosis. Interestingly, in the early stages of the response to malonate treatment, nuclear TDP-43 expression increased, and neurons remained relatively intact, without inclusion bodies or fragmentation. Therefore, we hypothesized that the increase of nuclear TDP-43 expression might be a pro-survival factor against oxidative stress injury. This hypothesis was confirmed by an in vitro transgenic experiment, in which overexpression of wild type mouse TDP-43 in cultured cortical motor neurons significantly reduced malonate-induced neuronal death. Our findings suggest that the loss of function of TDP-43 is an important cause of neuronal degen- eration, and upregulation of nuclear TDP-43 expression might be neuroprotective in amyotrophic lateral sclerosis.     

丙戊酰胺的又一合成法

丙二酸环异亚丙酯与正溴丙烷在无水碳酸钾和相转移催化剂 TBAB 存在下进行烷基化反应,得到2,2-二丙基丙二酸环异亚丙酯。后者用浓氨水进行氨解得到丙戊酰胺,此法较为简便。     

Time course of oxidative stress, lesion and edema after intrastriatal injection of malonate in rat: effect of alpha-phenyl-N-tert-butylnitrone

The aim of this study was to characterize the model of oxidative stress consisting in the infection of malonate (3 mumol), an inhibitor of mitochondrial complex II, in the rat striatum. The striatal concentrations of both the reduced and oxidized forms of glutathione (the major endogenous antioxidant) were determined at various times after malonate injection (1-4 h) in order to evaluate the evolution of oxidative stress. The progression of lesion size and edema was also determined up to 24 h after malonate administration. Finally, the effect of alpha-phenyl-N-tert-butylnitrone (PBN), an antioxidant nitrone, was studied. The levels of reduced glutathione (GSH) progressively decreased after malonate injection up to 40% of those of sham animals at 4 h. An increase in the concentrations of oxidized glutathione (GSSG) was also observed as early as 1 h after malonate administration which was maintained up to 4 h. The size of the lesion was maximal within 2 h of malonate injection, whereas edema continued to increase between 2 and 24 h. Injection of PBN at 100 mg/kg i.p. 30 min before and 2 h after malonate administration abolished the GSSG increase caused by malonate but did not modify the drop in GSH. This moderate antioxidant effect of PBN was associated with a slight decrease of the lesion area at two levels (10.7 and 10.2 mm anterior to the interaural line), but the lesion volume remained unchanged. By contrast, PBN reduced edema by 30%. Taken together, these results show that malonate induced a severe oxidative stress leading to the rapid development of the lesion. PBN demonstrates anti-edematous properties that are not sufficient to reduce the lesion.     

Separation of no-carrier-added rhenium from bulk tantalum by the sodium malonate–PEG aqueous biphasic system

The aqueous biphasic system (ABS) involving sodium malonate–polyethylene glycol (PEG) phases has been applied for the first time for separation of no-carrier-added ¹⁸³Re (T_1/2=70 d) from α-particle irradiated bulk tantalum target. The various ABS conditions were applied for investigating the separation by varying pH, temperature, PEG-molecular weight, concentration of salt. The extraction pattern was hardly affected by change in pH and the molecular weight of PEG. One step separation of nca ¹⁸³Re from Ta was achieved at the optimal conditions of (i) 50% (w/w) PEG-4000—2 M sodium malonate, 40 °C and (ii) 50% (w/w) PEG-4000—3 M sodium malonate, room temperature (27 °C).     

6-Hydroxydopamine Injections into the Nigrostriatal Pathway Attenuate Striatal Malonate and 3-Nitropropionic Acid Lesions

The mitochondrial inhibitors malonate and 3-nitropropionic (3NP) acid are potent neurotoxinsin vivo.Administration of these compounds results in neuronal loss similar to that seen in Huntington's disease. Although the mechanism of cell death produced by these compounds likely involves activation ofN-methyl- -aspartate receptors, it remains unclear why the striatum demonstrates regional susceptibility to the toxicity of these and other mitochondrial poisons. We hypothesized that dopamine, a weak neurotoxin that occurs in high concentrations in the striatum, may contribute to the neuronal damage caused by mitochondrial inhibition. We investigated whether depletion of striatal dopamine using the catecholaminergic toxin 6-hydroxydopamine would attenuate lesions induced by mitochondrial inhibition. We found that dopamine depletion reduced significantly the extent of histological damage in the striatum elicited by both intraparenchymal injections of 0.8 μmol malonate and 20 mg/kg systemic administration of 3NP. These data suggest that dopamine or one of its metabolites may contribute to mitochondrial toxin-induced cell death.     

Mice overexpressing 70-kDa heat shock protein show increased resistance to malonate and 3-nitropropionic acid

Heat shock proteins (HSPs) are induced in response to oxidative stress, hypoxia-ischemia, and neuronal injury and play a protective role. Malonate and 3-nitropropionic acid (3-NP) are well-characterized animal models of Huntington's Disease (HD). They inhibit succinate dehydrogenase, inducing mitochondrial dysfunction, which triggers the generation of superoxide radicals, secondary excitotoxicity, and apoptosis. In this study, we examined whether the 70-kDa heat shock protein (HSP-70) is protective against neurotoxicity induced by malonate and 3-NP. Homozygous and heterozygous HSP-70 overexpressing mice (HSP-70+/+, HSP-70+/-) and wild-type controls received 3-NP or malonate and striatal lesion sizes were evaluated by stereology. Compared to HSP-70+/+ and HSP-70+/-, wild-type controls showed significantly larger striatal lesions following 3-NP or malonate injections. These findings support the idea that HSP-70 has a neuroprotective role that may be useful in the treatment of neurodegenerative diseases.